Neonatal respiratory distress syndrome Neonatal Diseases Respiratory distress syndrome
Conditions
Interventions
Eligible women will be randomised to either 100 mg vaginal progesterone or placebo treatment groups.
Sponsors
The University of Adelaide (Australia)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Pregnant women with a history of prior spontaneous preterm birth at less than 34 weeks gestation.
Exclusion criteria
Exclusion criteria: Women with preterm prelabour ruptured membranes, active labour (defined as the presence of uterine activity and cervical dilatation greater than 3 cm), known fetal anomaly, or any contraindication to progesterone therapy or to continuation of the pregnancy (e.g. chorioamnionitis requiring delivery).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neonatal lung disease | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adverse outcomes for the woman 2. Maternal emotional wellbeing 3. Adverse outcomes for the infant 4. Costs of health care | — |
Countries
Australia
Outcome results
None listed